endpts.com Open in urlscan Pro
143.204.215.22  Public Scan

Form analysis
1 forms found in the DOM

https://endpts.com/

<form action="https://endpts.com/">
  <input type="text" name="s" placeholder="Search">
  <button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>

Text Content

 * Channels
   * All News
   * In Focus
   * Special
   * AI
   * Bioregnum
   * Biotech Voices
   * Cell/Gene Tx
   * China
   * Coronavirus
   * Deals
   * Diagnostics
   * Discovery
   * FDA+
   * Financing
   * Law
   * Letters to the Editor
   * Manufacturing
   * Marketing
   * Opinion
   * Outsourcing
   * Peer Review
   * People
   * Pharma
   * R&D
   * Startups
   * Weekly
 * Webinars
 * Biopharma Jobs
 * More
   * Work at Endpoints
   * Letter to Editors
   * IPO Tracker
   * Webinars
   * Events
   * Sponsored Posts
   * Advertise
   * Privacy Policy
   * Endpoints Merch
   * About Us
   * Help


 * SIGN UP
 * LOG IN




TOP STORIES


FOR­GET TIG­IT: NO­VAR­TIS’ $1B BET ON BEIGENE’S OCIPER­LIMAB ENDS AF­TER
COM­PETI­TORS’ SET­BACKS

3 hours ago
Deals
R&D



ADC THER­A­PEU­TICS PAUS­ES ZYN­LON­TA TRI­AL EN­ROLL­MENT AF­TER SEV­EN
PA­TIENT DEATHS, FIVE SE­RI­OUS SAFE­TY EVENTS

2 hours ago
R&D


BAKX THER­A­PEU­TICS TO SHUT DOWN AF­TER ‘SCI­EN­TIF­IC CHAL­LENGES’ AND
FI­NANC­ING DOL­DRUMS

3 hours ago
People
Startups


NAME THAT HU­MI­RA BIOSIM­I­LAR: IN­SIDE THE COM­PLI­CAT­ED PROCESS TO BRAND THE
NEWEST VER­SIONS OF AB­B­VIE'S DRUG

51 minutes ago
Pharma
Marketing


LATEST

Most read


EU­RO­PEAN REG­U­LA­TORS IN­VES­TI­GAT­ING RE­PORTS OF SUI­CIDE RISK IN
PA­TIENTS TAK­ING NO­VO NORDISK MEDS FOR WEIGHT LOSS

Yesterday
Pharma
Marketing


BRIS­TOL MY­ERS RE­IN­FORCES NEU­RO­SCIENCE DEALS; IO­VANCE PRICES $150M PUB­LIC
OF­FER­ING

2 hours ago
News Briefing


XSPRAY PHAR­MA HAND­ED CRL FROM US REG­U­LA­TORS SEEK­ING MORE IN­FOR­MA­TION
ABOUT LEUKEMIA TREAT­MENT

3 hours ago
FDA+
Manufacturing


EX­CLU­SIVE: BRIG­GS MOR­RISON'S CROSS­BOW THER­A­PEU­TICS NABS $80M FROM MPM,
PFIZ­ER VEN­TURES, LIL­LY IN HUNT FOR BET­TER ...

6 hours ago
Financing
Startups


EX­CLU­SIVE: PFIZ­ER TO IN­VEST $25M IN­TO TINY UK BIOTECH WITH EPI­GE­NET­ICS
AP­PROACH TO CAN­CER

6 hours ago
Financing
Deals


SEPTER­NA’S $150M IN­FU­SION WILL HELP PROVE WHETHER IT’S GOT THE RIGHT PILL FOR
HY­POPARATHY­ROIDISM

6 hours ago
Financing
Startups
see latest stream
People


EI­SAI’S US CHAIR, GLOB­AL ALZHEIMER’S LEADER TO RE­TIRE WEEKS AF­TER LEQEM­BI
AP­PROVAL

7 hours ago


JEFF LEERINK TALKS ABOUT WHY HE'S RES­UR­RECT­ING LEERINK PART­NERS AF­TER
BUY­ING HIS FIRM BACK FROM BANK­RUPT SVB

4 days ago


SUM­IT­O­MO WILL LAY OFF 62 NEW YORK WORK­ERS AF­TER CON­SOL­I­DAT­ING SEV­EN
SUB­SIDIARIES

4 days ago
Financing


APOGEE AND SAGIMET’S IPO PLANS COME IN­TO VIEW, WITH TAR­GET­ED RAIS­ES OF $228M
AND $66M

Yesterday


WUXI BI­O­LOG­ICS SEEKS SPIN­OUT, HK LIST­ING OF BIO­CON­JU­GATES-FO­CUSED JOINT
VEN­TURE

Yesterday


CAL­I­FOR­NIA ALZHEIMER'S START­UP TRUE­BIND­ING RAIS­ES MORE THAN $50M, LAYS
OFF WORK­ERS TWICE IN JUNE

4 days ago
Startups


BEIGENE FUR­THER IN­VESTS IN AD­CS WITH SOL­ID TU­MOR PART­NER DU­AL­I­TY­BIO, A
BION­TECH COL­LAB­O­RA­TOR

Yesterday


GAL­VA­NIZE TURNS TO LAY­OFFS LESS THAN A YEAR AF­TER MERG­ING THREE AP­PLE TREE
COM­PA­NIES, RAIS­ING $100M

5 days ago


GENE THER­A­PY BIOTECH CAP­SI­DA LAYS OFF WORK­ERS AF­TER EX­PAND­ING AB­B­VIE
PACT, ADDING LIL­LY COL­LAB

Last week
Deals


ASTEL­LAS EYES RARE OPH­THAL­MOL­O­GY, LI­CENS­ING 4DMT'S VI­RAL VEC­TOR FOR
GENE THER­A­PY FOR UP TO $962M

18 hours ago


MELIN­TA SE­CURES $142M BAR­DA DEAL TO TAR­GET PE­DI­ATRIC AND 'BIO­THREAT'
IN­DI­CA­TIONS FOR AN­TIBI­OTICS

22 hours ago


FUL­CRUM INKS DIS­COV­ERY DEAL WITH CAMP4 THER­A­PEU­TICS

Yesterday



IN FOCUSSEE ALL


‘THE SLEEP­ING GI­ANT IS WAK­ING UP’: FTC RAIS­ES THE PRES­SURE ON PHAR­MA
DEAL­MAK­ING

3 weeks ago
Deals
Pharma


'MOD­ER­NA WILL BE A RARE DIS­EASE COM­PA­NY,' CEO SAYS, AS MR­NA COM­PA­NY
PLOTS EX­PAN­SION IN GE­NET­IC DIS­EASES AND EYES ...

4 weeks ago
R&D
Pharma


ES­CAP­ING AN IM­PROB­A­BLE UP­BRING­ING, GREG VER­DINE PLACES HIS BIGGEST
CA­REER BETS IN DRUG­GING THE ‘UN­DRUG­GABLE’

Last month
People


RICH HOR­GAN SPEAR­HEAD­ED A GENE THER­A­PY FOR HIS BROTH­ER. THE TRI­AL END­ED
IN TRAGEDY, BUT THE WORK CON­TIN­UES FOR MORE ...

Last month
Cell/Gene Tx


ENDPOINTS STANDOUTS


WHO’S SPEND­ING AND WHO’S CUT­TING FROM BIG PHAR­MA’S $127B R&D BUD­GET? HERE
ARE THE TOP 15 PLAY­ERS

3 months ago
R&D
Special


A RA­DIOAC­TIVE PROSTATE CAN­CER THER­A­PY IS A LAST LIFE­LINE FOR PA­TIENTS.
NO­VAR­TIS CAN'T MAKE ENOUGH OF IT

4 months ago
R&D
In Focus


THE TOP 100 BIOTECH VCS: WHO'S STAY­ING AT THE TA­BLE AND WHAT DO THEY WANT NOW?

4 months ago
Financing
Deals


#JPM23: IS 2023 GO­ING TO BE A BET­TER YEAR FOR BIOTECH DEAL­MAK­ING?

5 months ago


PEER REVIEW SEE ALL

Jul
7


LYNN SEELY BRINGS EX-MY­OVANT COL­LEAGUE TO LYEL­L'S C-SUITE; NKAR­TA, ZAI LAB
NAME NEW CFOS

Jun
30


EX-GALA­PA­GOS MED­ICAL CHIEF HEADS TO UNIQURE; MAR­TIN MACK­AY LINES UP
RALLY­BIO SUC­CES­SOR

Jun
23


SE­BAS­T­IAN GUTH SHARP­ENS HIS FO­CUS AT BAY­ER; AS CD47 STRUG­GLES PER­SIST,
I-MAB AP­POINTS CEO

Jun
16


EX-METACRINE CHIEF PRE­STON KLASSEN RECHARGES AT MI­CROR­NA BIOTECH; AL­LO­GENE
BE­GINS SEARCH FOR A CFO

Jun
9


CHEMOMAB CHANGES CEOS, SUS­PENDS MID-STAGE TRI­AL; EX-FDA VAC­CINE OF­FI­CIAL
LENDS MORE HELP TO MESOBLAST


PHARMA CHANNEL FEED

21 hours ago


NO­VAR­TIS FACES ONE WIN, ONE LOSS IN PATENT CAS­ES OVER BLOCK­BUSTER HEART
FAIL­URE DRUG

No­var­tis record­ed both a win and a loss last week in patent fights over its
block­buster heart drug En­tresto.

READ MORE


BERNIE SANDERS WANTS HHS TO LOOK IN­TO THE PRICE OF EI­SAI'S NEW­LY AP­PROVED
ALZHEIMER'S DRUG

22 hours ago
Law


PFIZ­ER ADDS SHIFTS, IN­VESTS RE­SOURCES TO COPE WITH SURGE IN DE­MAND FOR
SYPHILIS TREAT­MENT

3 days ago
Manufacturing
latest in Pharma


IRA WILL RE­DUCE OUT-OF-POCK­ET SPEND­ING AMONG SOME PART D EN­ROLLEES BY $7.4B
IN 2025, HHS RE­PORT SAYS

3 days ago


CDC TO RE­DUCE FUND­ING FOR STATES’ CHILD VAC­CI­NA­TION PRO­GRAMS

4 days ago


NO­VO NORDISK FILES SEC­OND ROUND OF LAW­SUITS AGAINST COM­POUND­ING
PHAR­MA­CIES HAWK­ING IL­LE­GAL SEMAGLU­TIDE

4 days ago


FDA GRANTS FULL AP­PROVAL TO LEQEM­BI, OPEN­ING UP COV­ER­AGE OF ALZHEIMER’S
DRUG BY MEDICARE

4 days ago
FDA+


GAO SAYS FDA'S AL­LOWANCE OF PHAR­MA­CIES TO DIS­PENSE ABOR­TION PILL WAS NOT
SUB­JECT TO CON­GRES­SION­AL RE­VIEW

4 days ago
FDA+
see latest stories


MARKETING CHANNEL FEED

22 hours ago


AVADEL LAUNCH­ES QUICK START TO NAR­COLEP­SY DRUG’S MAR­KET­ING AF­TER LONG ROAD
TO AP­PROVAL

Avadel Phar­ma­ceu­ti­cals fired up its mar­ket­ing en­gine and de­buted
ad­ver­tis­ing for its nar­colep­sy drug Lum­ryz just weeks af­ter its full FDA
ap­proval in May. But it wasn’t ex­act­ly ...

READ MORE


LIL­LY RE­NEWS TEAM USA OLYMPIC AND PAR­A­LYMPIC SPON­SOR­SHIP AND SIGNS ON FOR
LOS AN­GE­LES 2028 GAMES

3 days ago
Pharma


BOEHRINGER IN­GEL­HEIM UN­VEILS LAT­EST FASH­ION IN­SPIRED BY RARE SKIN
DIS­EASE, CRE­AT­ED BY DE­SIGN STU­DENTS AND MEN­TORS

3 days ago
Pharma
latest in Marketing


SPRING­WORKS STALLED IN PRE-LAUNCH MODE FOR BRAND COM­MU­NI­CA­TIONS AF­TER FDA
DE­CI­SION DE­LAY

4 days ago
Pharma


AS­TRAZENECA LAUNCH­ES AWARE­NESS CAM­PAIGNS FOR PHYSI­CIANS AND PA­TIENTS WITH
DUAL ASTH­MA MES­SAGE

4 days ago
Pharma


J&J LEADS PHAR­MA COM­PA­NIES IN BRAND RANK­INGS, TOP­PING ROCHE, BAY­ER AND
PFIZ­ER AMID OVER­ALL IN­DUS­TRY DE­CLINE

5 days ago
Pharma


J&J TACK­LES MED­ICAL IL­LUS­TRA­TION IN­EQUITY WITH FREE DATA­BASE OF DI­VERSE
IM­AGES

Last week
Pharma


RE­VANCE THER­A­PEU­TICS PUSH­ES BOTOX 'BREAKUP' IN LAT­EST CAM­PAIGN FOR RI­VAL
COS­MET­IC DRUG

Last week
Pharma
see latest stories


FDA+ CHANNEL FEED

3 days ago


NEW PRO­VI­SION­AL, TIME-LIM­IT­ED DRUG AP­PROVAL PATH­WAY: HOUSE AND SEN­ATE
REIN­TRO­DUCE BI­PAR­TI­SAN BILL

Mem­bers of the House on both sides of the aisle joined with Sen­ate col­leagues
late last month in rein­tro­duc­ing a bill that would al­low for
ex­per­i­men­tal drugs for life-threat­en­ing dis­eases ...

READ MORE


NO MORE FDA AD­COMM VOTES? RE­FORMS BREW AS NEW RE­SEARCH HIGH­LIGHTS DE­CLINE
IN MEET­INGS

4 days ago


GENEN­TECH YANKS GAVRE­TO'S RARE THY­ROID CAN­CER IN­DI­CA­TION, MONTHS BE­FORE
HAND­ING IT BACK TO BLUE­PRINT

5 days ago
Pharma
latest in FDA+


FDA LIFTS PAR­TIAL HOLD ON CURIS' PHI/II LEUKEMIA STUDY AS BIOTECH RAIS­ES $15M 

5 days ago
Financing


BERNIE SANDERS WANTS TO ADD PRICE CAPS TO THER­A­PIES DE­VEL­OPED WITH BAR­DA,
CDC FUNDS

6 days ago
Law


MOD­ER­NA FILES RSV VAC­CINE FOR OLD­ER ADULTS IN US AND EU­ROPE

6 days ago


FDA RE­JECTS AM­NEAL'S EX­TEND­ED-RE­LEASE PARKIN­SON'S TREAT­MENT, SEEK­ING
MORE SAFE­TY DA­TA

6 days ago


FDA SAYS IP­CA LABS FAILED TO AD­DRESS QUAL­I­TY IS­SUES WITH BAD API BATCH­ES

Last week
Manufacturing
see latest stories


MANUFACTURING CHANNEL FEED

22 hours ago


NO­VAR­TIS AND SAM­SUNG INK FIVE-YEAR, $309M EX­PAN­SION TO BI­O­LOG­ICS
MAN­U­FAC­TUR­ING PART­NER­SHIP

Sam­sung Bi­o­log­ics dis­closed Mon­day that it's sig­nif­i­cant­ly ex­pand­ing
a 2022 pact with No­var­tis to help with the Swiss com­pa­ny's bi­o­log­ics
man­u­fac­tur­ing.

READ MORE


FDA SHIFTS HOW IT PRI­OR­I­TIZES WHICH PHAR­MA SITES TO IN­SPECT

5 days ago
R&D


MAN­U­FAC­TUR­ING ROUNDUP: GEN­SCRIPT TO BOOST PRO­DUC­TION CA­PAC­I­TY; SK
BIO­SCIENCES INKS MOU FOR ITS VAC­CINE IN THAI­LAND

5 days ago
latest in Manufacturing


FDA RAIS­ES CLEAN­ING AND QUAL­I­TY CON­CERNS AT AN­OTH­ER IP­CA
LAB­O­RA­TO­RIES MAN­U­FAC­TUR­ING SITE IN IN­DIA

5 days ago
Pharma


THER­MO FISH­ER TO AC­QUIRE DA­TA IN­TEL­LI­GENCE COM­PA­NY CORE­VI­TAS FOR
$900M+

5 days ago
Deals
Pharma


Q&A: FU­JI­FILM DIOSYNTH’S NEW CEO LARS PE­TERSEN TALKS PRI­OR­I­TIES AND PLANS
FOR THE CD­MO

5 days ago
People


TE­VA RE­PORT­ED­LY CON­SID­ER­ING SALE OF API UNIT

5 days ago
Deals


SANOFI INKS DEAL TO HELP SAU­DI ARA­BIA MAN­U­FAC­TURE VAC­CINES LO­CAL­LY

5 days ago
Deals
see latest stories

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas




LATEST

 * All News
 * Special
 * In Focus
   


CHANNELS

 * AI
 * Bioregnum
 * Biotech Voices
 * Cell/Gene Tx
 * China
 * Coronavirus
 * Deals
 * Diagnostics
 * Discovery
 * FDA+
 * Financing
 * Law
 * Letters to the Editor
 * Manufacturing
 * Marketing
 * Opinion
 * Outsourcing
 * Peer Review
 * People
 * Pharma
 * R&D
 * Startups
 * Weekly


MORE

 * Work at Endpoints
 * Letter to Editors
 * IPO Tracker
 * Events
 * Webinars
 * Sponsored Posts
 * Advertise
 * Endpoints Merch
 * About Us
 * Help


WORK IN BIOTECH

 * Endpoints Careers

© Endpoints News 2023

 * Help
 * Advertise
 * Privacy Policy
 * Business Model




LOG IN TO YOUR ACCOUNT


E-MAIL




PASSWORD


Change my password Get a magic email link
LOG IN


REQUEST MAGIC LINK

If you're already an Endpoints subscriber, enter your email below for a magic
link that lets you log in quickly without using a password. Please note the
magic link is one-time use only and expires after 24 hours.


EMAIL


BACK
REQUEST


RESET PASSWORD

We'll e-mail you a link to set a new password. Please note this link is one-time
use only and is valid for only 24 hours.


EMAIL


BACK
RESET


ABOUT YOU







SUBSCRIPTIONS

ENDPOINTS NEWS Daily at 11:30 AM ET



EARLY EDITION Daily at 7:15 AM ET



ENDPOINTS PHARMA Daily at 2 PM ET



BREAKING NEWS ALERTS 2-3 times a week



ENDPOINTS MARKETING RX Tue at 2 PM ET



ENDPOINTS FDA+ Wed at 2 PM ET



ENDPOINTS MANUFACTURING Thu at 2 PM ET



ENDPOINTS WEEKLY Sat at 6 AM ET


INSTANT SIGN UP